Abstract 4231: Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatmentAnna Bartosik, Krzysztof Brzózka, Kamil Kuś et al.|Cancer Research|2025Cited by 1
Novel method of measurement of in vitro drug uptake in OATP1B3 overexpressing cells in the presence of dextranAnna Kowal-Chwast, Kamil Kuś, Ewelina Gabor-Worwa et al.|Pharmacological Reports|2024Cited by 0